首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT)

【24h】

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT)

机译：II期无丙二醇美法仑（Evomela）与卡莫司汀，依托泊苷和阿糖胞苷（BEAM）联合用于自体干细胞移植（ASCT）淋巴瘤患者的清髓条件的II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2016年第1期|共1页
作者
Cashen Amanda; Gosch Kendall; Fletcher Theresa; Ceriotti Connie; Ghobadi Armin; Vij Ravi; Stockerl-Goldstein Keith; DiPersio John F.; Abboud Camille;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
入库时间 2022-08-18 09:02:17

相似文献

外文文献
中文文献
专利

1. Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT) [J] . Cashen Amanda, Gosch Kendall, Fletcher Theresa, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：II期无丙二醇美法仑（Evomela）与卡莫司汀，依托泊苷和阿糖胞苷（BEAM）联合用于自体干细胞移植（ASCT）淋巴瘤患者的清髓条件的II期研究
2. A Phase lib, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation [J] . Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第12期

机译：大剂量，无丙二醇盐注射用美法仑盐酸盐注射液（EVOMELA）用于多发性骨髓瘤患者自体移植的清髓治疗的阶段性，多中心，开放标签，安全性和有效性研究
3. Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. [J] . Julie M Vose, Shelly Carter, Linda J Burns, Journal of Clinical Oncology . 2013,第13期

机译：利妥昔单抗/卡莫司汀，依托泊苷，阿糖胞苷和美法仑（BEAM）与碘131托西单抗/ BEAM与自体造血细胞移植治疗复发性弥漫性大B细胞淋巴瘤的III期随机研究：来自BMT CTN 0401试验的结果。
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase III Randomized Study of Rituximab/Carmustine Etoposide Cytarabine and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial [O] . Julie M. Vose, Shelly Carter, Linda J. Burns, -1

机译：利妥昔单抗/卡莫司汀依托泊苷阿糖胞苷和美法仑（BEAM）与碘131 Tositumomab / BEAM与自体造血细胞移植治疗复发性弥漫性大B细胞淋巴瘤的III期随机研究：来自BMT CTN 0401试验的结果
7. Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT) [O] . Amanda Cashen, Kendall Gosch, Theresa Fletcher, 2016

机译：无丙二醇 - 无丙醇 - 无素蛋白酶（EVOMELA）的II期研究与氨基脲素，依托磷脂和红皂苷（梁）在淋巴瘤患者中进行髓鞘调节，经历自体干细胞移植（ASCT）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号